Isolation of Neutralizing Human Single Chain Antibodies Against Conserved Hemagglutinin Epitopes of Influenza a Virus H3N2 Strain

Overview

Journal Rep Biochem Mol Biol

Specialty Biochemistry

Date 2020 Apr 11

PMID 32274402

Citations 1

Authors

Mahboubeh Poursiami

Setareh Moazen

Foroogh Nejatollahi

Afagh Moatari

Affiliations

Soon will be listed here.

Abstract

Background: Immunotherapies using monoclonal antibodies against influenza A hemagglutinin (HA) has been an effective means for controlling Influenza spread. An alternative method for viral prophylaxis and treatment is the development of human single-chain variable fragment (scFv) antibodies with no human anti-mouse antibody (HAMA) response and high specificity. In the present study, two highly conserved sequences of HA were used to select specific neutralizing scFvs against H3N2 strain of influenza A virus.

Methods: Biopanning process was performed to isolate specific scFv antibodies against highly conserved HA sequences, aa173-181 and 227-239, of the influenza A H3N2 strain from a scFv library. The peptide-binding specificity of the selected clones was examined via phage ELISA. The soluble forms of the clones were prepared and assessed using western blot analysis and neutralization efficiency of the selected clones were examined by TCID50 neutralizing assay and real-time PCR.

Results: scFv 1 and scFv 2 were selected against HA of H3N2 influenza A virus with frequencies of 95% and 30% in the panning process, respectively. Western blot analysis confirmed the scFv band size. Significant neutralization in the presence of scFv 1 and scFv 2 were obtained. Real time PCR revealed significant decrease in viral copy number.

Conclusion: Two specific neutralizing scFvs against two highly conserved neutralizing epitopes of the influenza A virus HA glycoprotein were selected. A strong neutralization effect of scFv1, showed the potential of this antibody for H3N2 influenza A controlling in the viral spread.

Citing Articles

Characterization of an intracellular humanized single-chain antibody to matrix protein (M1) of H5N1 virus.

Sun H, Wu G, Zhang J, Wang Y, Qiu Y, Man H PLoS One. 2022; 17(3):e0266220.

PMID: 35358257 PMC: 8970388. DOI: 10.1371/journal.pone.0266220.

References

Nooreddin Faraji S, Nejatollahi F, Tamaddon A, Mohammadi M, Aminsharifi A . Generation and characterization of a specific single-chain antibody against DSPP as a prostate cancer biomarker: Involvement of bioinformatics-based design of novel epitopes. Int Immunopharmacol. 2019; 69:217-224. DOI: 10.1016/j.intimp.2019.01.016. View

Thathaisong U, Maneewatch S, Kulkeaw K, Thueng-In K, Poungpair O, Srimanote P . Human monoclonal single chain antibodies (HuScFv) that bind to the polymerase proteins of influenza A virus. Asian Pac J Allergy Immunol. 2008; 26(1):23-35. View

LaBarre D, Lowy R . Improvements in methods for calculating virus titer estimates from TCID50 and plaque assays. J Virol Methods. 2001; 96(2):107-26. DOI: 10.1016/s0166-0934(01)00316-0. View

Dreyfus C, Laursen N, Kwaks T, Zuijdgeest D, Khayat R, Ekiert D . Highly conserved protective epitopes on influenza B viruses. Science. 2012; 337(6100):1343-8. PMC: 3538841. DOI: 10.1126/science.1222908. View

Mohammadi M, Nejatollahi F, Ghasemi Y, Faraji S . Anti-Metastatic and Anti-Invasion Effects of a Specific Anti-MUC18 scFv Antibody on Breast Cancer Cells. Appl Biochem Biotechnol. 2016; 181(1):379-390. DOI: 10.1007/s12010-016-2218-1. View

Mohammadi M, Nejatollahi F, Sakhteman A, Zarei N . Insilico analysis of three different tag polypeptides with dual roles in scFv antibodies. J Theor Biol. 2016; 402:100-6. DOI: 10.1016/j.jtbi.2016.04.016. View

Sui J, Hwang W, Perez S, Wei G, Aird D, Chen L . Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol. 2009; 16(3):265-73. PMC: 2692245. DOI: 10.1038/nsmb.1566. View

Aoki F, Macleod M, Paggiaro P, Carewicz O, El Sawy A, Wat C . Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother. 2002; 51(1):123-9. DOI: 10.1093/jac/dkg007. View

Subbarao K, Matsuoka Y . The prospects and challenges of universal vaccines for influenza. Trends Microbiol. 2013; 21(7):350-8. PMC: 3700639. DOI: 10.1016/j.tim.2013.04.003. View

10.

Tamura M, Milenic D, Iwahashi M, Padlan E, Schlom J, Kashmiri S . Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only. J Immunol. 2000; 164(3):1432-41. DOI: 10.4049/jimmunol.164.3.1432. View

11.

Ahn I, Kim H, Jung S, Lee J, Son H . SimFlu: a simulation tool for predicting the variation pattern of influenza A virus. Comput Biol Med. 2014; 52:35-40. DOI: 10.1016/j.compbiomed.2014.06.003. View

12.

Moazen B, Ebrahimi E, Nejatollahi F . Single Chain Antibodies Against gp55 of Human Cytomegalovirus (HCMV) for Prophylaxis and Treatment of HCMV Infections. Jundishapur J Microbiol. 2016; 9(3):e16241. PMC: 4870390. DOI: 10.5812/jjm.16241. View

13.

OConnor S, Forsyth P, Dalal S, Evans P, Short M, Shiach C . The rapid diagnosis of acute promyelocytic leukaemia using PML (5E10) monoclonal antibody. Br J Haematol. 1997; 99(3):597-604. DOI: 10.1046/j.1365-2141.1997.4613266.x. View

14.

Clementi N, Criscuolo E, Castelli M, Clementi M . Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis. New Microbiol. 2012; 35(4):399-406. View

15.

van der Vries E, Schutten M, Fraaij P, Boucher C, Osterhaus A . Influenza virus resistance to antiviral therapy. Adv Pharmacol. 2013; 67:217-46. DOI: 10.1016/B978-0-12-405880-4.00006-8. View

16.

Flego M, Ascione A, Cianfriglia M, Vella S . Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases. BMC Med. 2013; 11:4. PMC: 3565905. DOI: 10.1186/1741-7015-11-4. View

17.

Taubenberger J . The origin and virulence of the 1918 "Spanish" influenza virus. Proc Am Philos Soc. 2007; 150(1):86-112. PMC: 2720273. View

18.

Park S, Jeong Y, Lee Y, Kim I, Seo S, Kim E . Hepatitis B virus-neutralizing anti-pre-S1 human antibody fragments from large naïve antibody phage library. Antiviral Res. 2005; 68(3):109-15. DOI: 10.1016/j.antiviral.2005.06.012. View

19.

Marasco W, Sui J . The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol. 2007; 25(12):1421-34. PMC: 7097443. DOI: 10.1038/nbt1363. View

20.

Nejatollahi F, Bayat P, Moazen B . Cell growth inhibition and apoptotic effects of a specific anti-RTFscFv antibody on prostate cancer, but not glioblastoma, cells. F1000Res. 2017; 6:156. PMC: 5399964. DOI: 10.12688/f1000research.10803.1. View